Clinical trials: Cancer, Bladder
Muscle Invasive Bladder Cancer, High Risk Urothelial Carcinoma of the Upper Urinary Tracts
Dose Dense MVAC for Muscle Invasive Bladder Cancer
Standard treatment for early stage bladder cancer is chemotherapy with methotrexate (M), vinblastine (V), adriamycin (A), and cisplatin (C) followed by surgical removal of any remaining cancer and the bladder with the intent of…
- Trial name
- NCT01031420
- Testing
- single arm dose dense MVAC
- Where
- 2 sites in United States
- Volunteers
- 54 people
- Sponsor
- Fox Chase Cancer Center
Urinary Bladder Neoplasms
CIK in Treating Patients With Bladder Cancer
Chemotherapy is the main treatment method for patients with Bladder Cancer. However, Relapse remains the major cause of treatment failure.Biological therapies such as CIK stimulate the immune system and stop tumor cells from…
- Trial name
- NCT02489890
- Testing
- Cytokine-induced Killer Cells
- Volunteers
- 1,500 people
- Sponsor
- The First People's Hospital of Changzhou
Cancer, All Types, Cancer of Liver
The PIONEER Initiative: Precision Insights On N-of-1 Ex Vivo Effectiveness Research Based on Individual Tumor Ownership (Precision Oncology)
The PIONEER Initiative stands for Precision Insights On N-of-1 Ex vivo Effectiveness Research. The PIONEER Initiative is designed to provide access to functional precision medicine to any cancer patient with any tumor at any…
- Conditions
- Cancer, All Types, Cancer of Liver, Cancer of Stomach, Cancer of Head and Neck
- Trial name
- PIONEER (NCT03896958)
- Where
- United States
- Volunteers
- 1,000 people
- Sponsor
- SpeciCare
Urothelial Cancer, Bladder Cancer
A Multi-Center Natural History of Urothelial Cancer and Rare Genitourinary Tract Malignancies
Background: Tumors in the genitourinary tracts can occur in the kidney, bladder, prostate, and testicles and can have common and rare histologies. Some cancers that occur along the genitourinary (GU) tract are rare.
- Conditions
- Urothelial Cancer, Bladder Cancer, Genitourinary Cancer, Urogenital Neoplasms
- Trial name
- NCT04923178
- Where
- United States
- Volunteers
- 1,100 people
- Sponsor
- National Cancer Institute (NCI)
Urologic Neoplasms, Urogenital Neoplasms
Stage II-IIIa Urothelial Cancer Randomizing Pre-operative Nivolumab With or Without Relatlimab
This is a non-blinded phase 2 trial in Stage II-IIIa urothelial cancer randomizing pre-operative nivolumab with or without relatlimab to assess whether bladder preservation after dual immunotherapy would be a viable treatment…
- Conditions
- Urologic Neoplasms, Urogenital Neoplasms, Neoplasms by Site, Neoplasms
- Trial name
- TURANDORELA (NCT06237920)
- Testing
- Nivolumab, Relatlimab
- Where
- 9 sites in Netherlands
- Volunteers
- 90 people
- Sponsor
- The Netherlands Cancer Institute
Urinary Bladder Neoplasms
Irreversible Electroporation(IRE) For Unresectable Urinary Bladder Neoplasms
The purpose of this study is to evaluate the safety and efficacy of irreversible electroporation (IRE) for unresectable Urinary Bladder Neoplasms.
- Trial name
- IRE (NCT02430623)
- Testing
- Irreversible electroporation (IRE), NanoKnife
- Where
- China
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Fuda Cancer Hospital, Guangzhou
Bladder Cancer, Transitional Cell Carcinoma
Lymph Node Processing Protocol for Radical Cystectomy and Pelvic Lymph Node Dissection in Bladder Cancer
When the bladder is removed for bladder cancer, pelvic lymph nodes (LN) are also removed. While the anatomic extent of this LN dissection is critical, the investigators often use the number of LN removed as a measure of the…
- Trial name
- NCT01395225
- Where
- Canada
- Volunteers
- 32 people
- Sponsor
- University of British Columbia
Intermediate or High-risk Bladder Cancer
Hexvix Photodynamic Therapy in Patients With Bladder Cancer
The purpose of the study is to investigate the safety and feasibility of Hexaminolevulinate based photodynamic therapy in patients with intermediate or high-risk transitional cell carcinoma of the bladder.
- Trial name
- NCT01303991
- Testing
- Hexvix PDT with Karl Storz T-Light
- Volunteers
- 17 people
- Sponsor
- Photocure
Carcinoma in Situ, Bladder Cancer
Intravesical AD 32 (Valrubicin) in Patients With Carcinoma in Situ (CIS) of the Bladder Who Have Failed or Have Recurrence Following Treatment With Bacillus Calmette-guerin (BCG)
This is a Phase II/Phase III study of intravesical AD 32 (valrubicin) in patients with carcinoma in situ (CIS) who have been previously treated with intravesical Bacillus Calmette-Guerin (BCG) for CIS and in whom recurrence or…
- Trial name
- Bladder Cancer (NCT01316874)
- Testing
- Valrubicin, 800 mg
- Where
- 39 sites in United States
- Volunteers
- 90 people
- Sponsor
- Endo USA Inc., a Keenova Therapeutics Company
Pancreatic Cancer, Colo-rectal Cancer
Prehabilitation in High-risk Oncologic Surgery
The goal of this clinical study is to learn whether a prehabilitation program can improve recovery after major abdominal surgery in adults with cancer who are receiving treatment before surgery.
- Conditions
- Pancreatic Cancer, Colo-rectal Cancer, Gastric Cancer, Esophageal Cancer
- Trial name
- NCT07638410
- Testing
- Multidisciplinary Prehabilitation Program
- Where
- United States
- Volunteers
- 180 people
- Sponsor
- Fox Chase Cancer Center
Urosepsis, Bladder Cancer
Antibiotic Prophylaxis in Transurethral Prostate Resection (TURP) and Transurethral Bladder Tumour Resection (TURB)
To investigate the use of antibiotic prophylaxis in patients undergoing TURP and TURB. The investigators set up a prospective, randomized controlled trial in which (after exclusion of risk factors) patients will be randomized in…
- Conditions
- Urosepsis, Bladder Cancer, Prostate Hyperplasia, Antibiotic Resistant Strain
- Trial name
- Prophylaxis001 (NCT04212403)
- Testing
- Levofloxacin
- Where
- Belgium
- Volunteers
- 1,350 people
- Sponsor
- Jessa Hospital
Advanced Colorectal Carcinoma, Metastatic Colorectal Carcinoma
Dasatinib for the Prevention of Oxaliplatin-Induced Neuropathy in Patients With Metastatic Gastrointestinal Cancer Receiving FOLFOX Chemotherapy With or Without Bevacizumab
This phase Ib trial studies side effects and best dose of dasatinib in preventing oxaliplatin-induced peripheral neuropathy in patients with gastrointestinal cancers who are receiving FOLFOX regimen with or without bevacizumab.
- Conditions
- Advanced Colorectal Carcinoma, Metastatic Colorectal Carcinoma, Stage IV Colorectal Cancer AJCC v8, Stage IVA Colorectal Cancer AJCC v8
- Trial name
- NCT04164069
- Testing
- Bevacizumab, Dasatinib, Fluorouracil
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- Anne Noonan
Bladder Cancer
Physical Therapy in Pre-cystectomy Patients
This single-site, non-randomized, study evaluates the impact of a physical therapy consultation for patients with bladder cancer scheduled for radical cystectomy (RC).
- Trial name
- NCT05978570
- Where
- United States
- Volunteers
- 68 people
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
Bladder Cancer, Gemcitabine and Cisplatin Chemotherapy
Transurethral Resection of Bladder Tumor (TURBT) Combined With Adjuvant Intravenous GC Chemotherapy for Non-muscle-invasive Bladder Cancer
It is still a challenge for urologic surgeon to prevent the post transurethral resection of bladder tumor (TURBT) recurrence of moderate-high risk non-muscle invasive bladder tumor.
- Conditions
- Bladder Cancer, Gemcitabine and Cisplatin Chemotherapy, Epirubicin Instillation, Recurrence
- Trial name
- NCT02716961
- Testing
- Gemcitabine, cisplatin
- Where
- China
- Volunteers
- 208 people
- Sponsor
- The First Affiliated Hospital with Nanjing Medical University
Bladder Cancer
Autophagy Bladder Cancer
Bladder cancer is the most common malignancy of the urinary tract. It represents the 7th most commonly diagnosed cancer in male population worldwide and drops to the 11th when both genders are considered .
- Trial name
- NCT03254888
- Where
- Egypt
- Volunteers
- 150 people
- Sponsor
- Assiut University
Muscle-Invasive Bladder Carcinoma
A Study of Risk Enabled Therapy After Neoadjuvant Immunochemotherapy for Bladder Cancer
Neoadjuvant accelerated methotrexate/vinblastine/adriamycin/cisplatin (AMVAC) in combination with nivolumab is under evaluation for the treatment of muscle invasive bladder cancer (MIBC).
- Trial name
- NCT04506554
- Testing
- AMVAC + Nivolumab
- Where
- 4 sites in United States
- Volunteers
- 81 people
- Sponsor
- Fox Chase Cancer Center
Bladder Cancer
Study of CAbozantinib in Combination with AtezolizumaB for Muscle-Invasive BladdEr Cancer
This is an open-label phase II study assessing the activity of cabozantinib combined with atezolizumab in patients with resectable muscle-invasive urothelial carcinoma who are ineligible for cisplatin-based therapy or decline…
- Trial name
- ABATE (NCT04289779)
- Testing
- Cabozantinib, Atezolizumab, Cystectomy
- Where
- 6 sites in United States
- Volunteers
- 46 people
- Sponsor
- Deepak Kilari
Bladder (Urothelial, Transitional Cell) Cancer, Kidney (Renal Cell) Cancer
Effectiveness of a Personalized 6-month Programme on Frailty in Older Patients Treated for Bladder or Kidney Cancer.
Bladder and kidney cancers are commonly diagnosed in older adults. Surgery remains the primary treatment modality for patients with kidney or bladder cancer.
- Trial name
- FRAGECO (NCT07073703)
- Testing
- APA, Therapeutic education workshops, DAPAP
- Where
- 2 sites in France
- Volunteers
- 106 people
- Sponsor
- Centre Hospitalier Universitaire de Saint Etienne
Bladder Cancer, Transitional Cell Cancer of the Renal Pelvis and Ureter
Gemcitabine Hydrochloride, Cisplatin, and Sunitinib Malate as First-Line Therapy in Treating Patients With Locally Advanced And/or Metastatic Transitional Cell Carcinoma of the Urothelium (SUCCINCT)
RATIONALE: Drugs used in chemotherapy, such as gemcitabine hydrochloride and cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Conditions
- Bladder Cancer, Transitional Cell Cancer of the Renal Pelvis and Ureter, Urethral Cancer
- Trial name
- NCT01089088
- Testing
- cisplatin, gemcitabine hydrochloride, sunitinib malate
- Where
- 16 sites in United Kingdom
- Volunteers
- 63 people
- Sponsor
- Cardiff University
Bladder Cancer, Non Muscle Invasive
Safety, Tolerability, and Preliminary Efficacy of BH011 in Subjects With Non-Muscle-Invasive Bladder Cancer
The purpose of this study is to determine the safety and tolerability of intravesical BH011 in patients with high-risk non-muscle invasive bladder cancer（NMIBC） after Bacillus Calmette-Guerin（BCG） failure and to assess the…
- Trial name
- NCT06732531
- Testing
- BH011
- Where
- 6 sites in China
- Volunteers
- 48 people
- Sponsor
- Zhuhai Beihai Biotech Co., Ltd
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.